# US 2017/0253643 A1 · Centrally-Acting Peptide Derivative, and Pharmaceutical Composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253643 A1
- Document ID: US20170253643A1
- Status: Published application
- Kind: A1
- Application number: 15/507,403
- Filed: 2015-09-02
- Published: 2017-09-07
- Earliest claimed: 2014-09-02
- Assignees: Tokyo University of Science Foundation
- Applicants: Tokyo University of Science Foundation
- Inventors: Chikamasa Yamashita; Jun-Ichiro Oka; Michiko Horiguchi; Sachie Sasaki-Hamada
- Web page: https://patentgrep.com/patent/US20170253643A1

## CPC

- C07K 14/605: Glucagons
- A61K 9/0043: {Nose}
- A61K 38/095: Oxytocins; Vasopressins; Related peptides
- A61K 38/2264: {Obesity-gene products, e.g. leptin}
- A61K 38/2271: {Neuropeptide Y}
- A61K 38/26: Glucagons
- A61K 38/28: Insulins
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A centrally-acting peptide derivative, including a centrally-acting portion, a cell-penetrating sequence portion, and an endosomal-escape portion.

## Claims

### Claim 1

A centrally-acting peptide derivative, comprising a centrally-acting portion, a cell-penetrating sequence portion, and an endosomal-escape portion.

### Claim 2 (depends on 1)

The centrally-acting peptide derivative according to claim 1, wherein the centrally-acting portion is an amino acid sequence portion that is derived from a peptide.

### Claim 3 (depends on 2)

The centrally-acting peptide derivative according to claim 2, wherein the amino acid sequence portion is derived from a peptide that is GLP-1, GLP-2, neuromedin U, an opioid peptide, oxytocin, leptin, orexin, neuropeptide Y, or insulin.

### Claim 4 (depends on 2)

The centrally-acting peptide derivative according to claim 2, wherein the amino acid sequence portion is derived from a peptide selected from the following (a1), (a2), (a3), or (b):
(a1) a peptide comprising an amino acid sequence represented by His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp (sequence number 1);
(a2) a peptide comprising an amino acid sequences represented by His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2 (sequence number 2);
(a3) a peptide comprising an amino acid sequence represented by Tyr-Lys-Val-Asn-Glu-Tyr-Gln-Gly-Pro-Val-Ala-Pro-Ser-Gly-Gly-Phe-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 (neuromedin U, sequence number 3); and
(b) a peptide comprising an amino acid sequence represented by any of (a1) to (a3) in which one or more amino acid residues are deleted, replaced or added, the peptide having a centrally-acting activity.

### Claim 5 (depends on 1)

The centrally-acting peptide derivative according to claim 1, used for treatment of a neuropsychiatric disorder.

### Claim 6 (depends on 1)

The centrally-acting peptide derivative according to claim 1, used for treatment of depression or a learning disorder.

### Claim 7 (depends on 1)

A pharmaceutical composition, comprising the centrally-acting peptide derivative according to claim 1 as an active ingredient.

### Claim 8 (depends on 7)

The pharmaceutical composition according to claim 7, used for treatment of a neuropsychiatric disorder.

### Claim 9 (depends on 7)

The pharmaceutical composition according to claim 7, used for treatment of depression or a learning disorder.

### Claim 10 (depends on 1)

A nasal formulation comprising the centrally-acting peptide derivative according to claim 1 as an active ingredient.

### Claim 11 (depends on 10)

The nasal formulation according to claim 10, used for treatment of a neuropsychiatric disorder.

### Claim 12 (depends on 10)

The nasal formulation according to claim 10, used for treatment of depression or a learning disorder.

### Claim 13 (depends on 1)

A method of using a pharmaceutical composition for intranasal administration, the pharmaceutical composition comprising the centrally-acting peptide derivative according to claim 1 as an active ingredient.

### Claim 14

A method of stabilizing a centrally-acting peptide, the method comprising adding a cell-penetrating sequence portion and an endosomal-escape portion to a centrally-acting peptide.

### Claim 15 (depends on 1)

The centrally-acting peptide derivative according to claim 1, wherein the centrally-acting portion is selected from the group consisting of GLP-1, GLP-2, and neuromedin U, the cell-penetrating sequence portion is selected from an oligoarginine represented by Rn where n is from 6 to 12, and the endosomal-escape portion is selected from the group consisting of FFLIPKG, LILIG, FFG, FFFFG, and FFFFFFG.
